Leitlinien zur Therapie des exokrinen Pankreaskarzinoms
R. Parwaresch, B. Bültmann, Margret Rave‐Fränk, T. Wiegel, Walter Hoffmann, D. Comely, E. Dühmke, M. Bamberg, M. Busch, Ulrich Vogel(Robert Koch Institute), C. Degner, W.E. Berdel, M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), A. Korfel, Katharina Holstein, T.M.M. de Reijke, M. Schiebe, I.-M. von Broen, T.A. Walter, N. Runkel, Dieter K. Hossfeld(Universität Hamburg), K. H. Kurth, T. Franke, H.J. Weh, K. Mross, D. H. J. Schamhart, Elizabeth C. de Boer, Y. Bankmann, P. Rudolph, K. Herbst
Cited by 3
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
|Journal of Clinical Oncology|2011|323